Results 161 to 170 of about 3,938 (215)

Complications of intrathecal Baclofen delivery

British Journal of Neurosurgery, 1992
The medical records of 46 consecutive patients who have had intrathecal Baclofen drug delivery systems implanted in the National Spinal Injuries Centre, the Paddocks Hospital Spinal Unit, Princes Risborough, Lodge Moor Hospital Spinal Unit, Sheffield, the Northern Regional Spinal Injuries Unit, Hexham and The Radcliffe Infirmary, Oxford, were reviewed.
A Jamous, Dajue Wang, J R Silver
exaly   +3 more sources

Intrathecal baclofen.

Bailliere's clinical neurology, 1994
The intrathecal application of the GABA-B agonist baclofen has become more and more popular for severe spinal spasticity. Since it was first introduced in 1984 more than 1000 patients worldwide have been treated by this method, using an implantable drug administration device.
Blair Ford, Stanley Fahn
  +5 more sources

Intrathecal Baclofen in Tetanus

Annals of the New York Academy of Sciences, 1986
Our understanding of the pathogenesis of tetanus stems from the end of the nineteenth century. In 1884 the transfer of the infective as well as toxic agent of tetanus infection was demonstrated in animals [10, 50]. Only a few years later tetanus bacilli were isolated from human victims [44, 64] and its toxin was characterized as the pathogenic link [29]
H, Müller, U, Börner, J, Zierski, G, Hempelmann   +3 more
openaire   +3 more sources

Spasticity and Intrathecal Baclofen

Seminars in Neurology, 2014
Severe spastic tone and/or spastic hypertonia can be the most disabling consequences of a neurologic insult, resulting from an excess of muscle tone. Baclofen, a GABA-B agonist, is one of the most widely used drugs in treating abnormal or disabling spastic tone.
Erin, Furr-Stimming, Allison M, Boyle, Mya C, Schiess   +2 more
openaire   +2 more sources

Intrathecal baclofen in pain management

Regional Anesthesia and Pain Medicine, 2004
Baclofen is a GABA(B) agonist that is administered spinally via an implanted drug delivery device to treat spasticity. It has been shown to have powerful antinociceptive effects in experimental animal models at doses that produce little or no motor-blocking effects but has rarely been used as a spinal analgesic agent in patients without spasticity ...
Marc, Slonimski, Stephen E, Abram, Robert E, Zuniga   +2 more
openaire   +2 more sources

Intrathecal baclofen therapy.

Irish medical journal, 2014
Leinster
Marc Sindou, George Georgoulis, Patrick Mertens   +2 more
openaire   +4 more sources

Complications of intrathecal baclofen therapy

Voprosy neirokhirurgii imeni N.N. Burdenko, 2017
To analyze complications of intrathecal baclofen therapy and identify high-risk groups.We implanted 52 pumps to spastic patients for chronic intrathecal baclofen infusion. Two groups of patients were distinguished: 23 patients with spinal spasticity (group 1) and 29 patients with cerebral spasticity (group 2).
D L, Paskhin, A V, Dekopov, A A, Tomsky, E D, Isagulyan, E M, Salova   +4 more
openaire   +2 more sources

Intrathecal Baclofen Overdose and Withdrawal

Pediatric Emergency Care, 2006
Intrathecal baclofen (ITB) therapy is being used increasingly to treat medically intractable spasticity in children with cerebral palsy and spinal cord injuries. Baclofen overdose and withdrawal are potentially life-threatening complications of pump and spinal catheter system malfunction. We report a case of a 12-year-old boy, on long-term ITB therapy,
Kelly W, Shirley, Sanjeev, Kothare, Joseph H, Piatt, Terry A, Adirim   +3 more
openaire   +2 more sources

Intrathecal baclofen for motor disorders

Movement Disorders, 1995
AbstractTo test the efficacy of intrathecal baclofen in various movement disorders, 18 patients with dystonia, head trauma, cerebral palsy, rigidity, or painful spasms underwent a trial of intrathecal baclofen. Ten went on to permanent implantation with an infusion pump to provide long‐term treatment.
R D, Penn, J M, Gianino, M M, York
openaire   +2 more sources

Intrathecal baclofen for severe spasticity

Medical Journal of Australia, 1986
The intrathecal administration of baclofen by way of an implanted subcutaneous drug delivery system is described in a patient with a severe spastic paraparesis due to multiple sclerosis. Intrathecally-administered baclofen is proposed as another therapeutic dimension and adjunct to physical therapy in the management of patients with severe spasticity ...
G J, Hankey, E G, Stewart-Wynne, D, Perlman   +2 more
openaire   +4 more sources